• Tuisblad
  • Market Watch
  • Ozempic and similar weight loss drugs may lower risk of 42 health conditions

Ozempic and similar weight loss drugs may lower risk of 42 health conditions

The American Food and Drug Administration's approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.
Henriette Lamprecht
Ziyad Al-Aly - Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they
...

Kommentaar

Republikein 2025-04-02

Geen kommentaar is op hierdie artikel gelaat nie

Meld asseblief aan om kommentaar te lewer